G7 Health Ministers: Pull incentives to support stewardship, access, and innovation

Dear All,

The G7 Health Ministers met 19-20 May 2022 in Berlin. As you might expect, their communique covered a range of topics but focused on four priority areas: (1) Overcoming COVID-19, (2) Future pandemic preparedness, (3) AMR, and (4) Health risks from climate change. You should review the entire communique; I will excerpt from their text on AMR (emphasis, bullet points, and links added for clarity:

  • (para. 24) “Antimicrobial resistance (AMR), and in particular resistance of bacteria to antibiotics (antibiotic resistance), is an urgent public health and socio-economic problem that has a profound effect on the world causing an estimated 1.27 million deaths attributable to antibiotic resistance in 2019.
    • Modern medicine depends on effective antibiotics.
  • (para. 30) “We recognise the urgent need to foster innovation and to strengthen the research and development (R&D) pipeline.
    • “We therefore highlight the importance of accelerating the early and late-stage development of urgently needed new antimicrobial drugs, vaccines, alternative therapeutics and diagnostics.
  • (para 31) “We acknowledge that it is essential to ensure a sustainable market for existing as well as new antibiotics.
    • “This includes appropriate steps to address antibiotic market failure and to ensure the commercialisation and provision of existing and new antibiotics for unmet public health needs while taking into account stewardship and equitable access.
    • “Building on the G7 Finance Ministers’ Statement of 2021 on Action to Support Antibiotic Development, we commit to expedite implementation of existing strategies and to take additional specific and appropriate steps in our domestic markets and health systems, underpinned by the 2021 G7 Shared Principles for the Valuation of Antimicrobial Therapeutics.”
      • Aside: There is a 14 Dec 2021 newsletter on these two important papers
      • 4 June 2022 addendum: The G7 Finance Ministers 20 May 2022 statement reiterates their support for addressing AMR in paragraph 11: “We reaffirm our commitments of December 2021 on actions to support antibiotic development and support the ongoing work of the G7 Health, Agriculture and Climate Environment and Energy Tracks on antimicrobial resistance (AMR). We welcome the AMR progress report by the World Health Organisation and the Global AMR R&D Hub and request a further detailed update on the progress made for G7 Finance and Health Ministers in 2023.”
      • 29 June 2022 addendum: The G7 Leaders met 26-28 June and their communique further supports the call for Pull incentives. For details, see the discussion in this 28 June 2022 newsletter.
    • “Recognising country-specific circumstances and member state competences, we will explore a range of market incentive options, with a particular emphasis on supporting relevant pull incentives.

Great stuff and well said! I especially like the very clear statement of the way that Pull incentives underpin access, stewardship and innovation: without a sustainable market, there is no access and stewardship is moot!

Please do read the full text (the AMR section starts on page 8 of the .pdf). Among other things, the full text includes shout outs to CARB-X, GARDP, the Global AMR R&D Hub, WHO, and the SECURE pilot project.

#AMRSOS! #SquashSuperbugs!  All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Current funding opportunities (most current list is here)


Upcoming meetings of interest to the AMR community (most current list is here):

  • [Not to be missed!] 8 Dec 2021: “The New Winds Pushing and Pulling Antibacterial Development.” This FABULOUS program featured talks from the UK team behind the NHS “Netflix” pilot, Kevin Outterson’s recently released report documenting the need for global Pull incentives to have a value of $2.2 – 4.8b, and speakers covering PASTEUR and work in the EU on pull incentives. The video is here — please make time to listen to this program!
  • [Required reading!] The stunning 4 Feb 2022 webinar for the GRAM report (Global Research on Antimicrobial Resistance “1.27 million deaths per year are directly attributable to AMR”) is now available for replay. #AMRSOS! 
  • 24 May 2022 (virtual, 1-2p East Coast), The Pew Charitable Trust is sponsoring an event with The Hill entitled “Antibiotic Resistance: A Looming Public Health Crisis.” Speakers will include US Senator Michael Bennet (D-CO) and US Representative Drew Ferguson (R-GA) as well as a patient survivor, IDSA, and CARB-X. Go here for details! 
  • 31 May 2022 (virtual, 15:00-18:00, Finland): “Antibiotics for Life”, a webinar sponsored by TGAR (The Global Antibiotics Resistance Foundation) that will discuss stewardship and innovation from a Nordic perspective. Go here to register.
  • 3 Jun 2022 (virtual, 9a-5p ET): FDA-sponsored workshop entitled “Drugs for the Treatment of Uncomplicated Urinary Tract Infections (UTI)” that will focus on “nonclinical and clinical considerations regarding antimicrobial drug development for uncomplicated UTI.” Go here for more details and to register.
  • 7 Jun 2022 (virtual, 9-10.30a East Coast). CDC-sponsored webinar entitled “Antifungal Resistance: Understanding this Growing Global Threat.” Hosted by the team at CDC’s Mycotic Diseases Division, this looks to be an excellent conversation. Go here to register.
  • 8-9 Jun 2022 (virtual, 15.00-18.00 CEST / 9.00-12.00 EDT on both days): “Expert Workshop on Monoclonal Antibodies for AMR Pathogens” sponsored by the Paul-Ehrlich-Institut, on behalf of the COMBINE project. Day 1 focuses on preclinical development and translation (register here); Day 2 focuses on recurring problems and mitigation strategies in the clinical development (register here).
  • 16-18 June 2022 (Perth, Australia): Australasian Society for Infectious Diseases Annual Scientific Meeting is a hybrid event for adult and pediatric infectious disease and clinical microbiology specialists. Go here for details.
  • 21 Jun 2022 (virtual, 10:00-11:00 ET | 15:00-16:00 BST): Launch of the AMR Register. Sponsored by Vivli with funding from many partners, this is the launch of an open-access repository for industry-generated surveillance data. Looks interesting! Go here to register.
  • 22-23 Jun 2022 (virtual, 10a to approx. 2.30p ET on both days): Workshop entitled “Strategies for Early-Stage Programs Developing Novel Antibacterial and Antifungal Drugs.” Sponsored by NIAID’s Bacteriology and Mycology Branch (BMB), this 2-day webinar features a very strong faculty (including speakers from FDA) discussing tips and insights for early product discovery including in-depth discussions of funding opportunities. The timing is US-centered but video replay will be available. Do not miss this! Go here to register.
  • 11-14 July 2022 (Sydney): Australian Society for Microbiology Annual National Meeting is a hybrid event that will feature a range of lectures and symposium sessions, as well as extensive opportunities for networking. Go here for details.
  • 24-27 July 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.
  • 28-31 July 2022 (Singapore): 10th International Congress of Asia Pacific Society of Infection Control is a hybrid event for professionals in the Asia Pacific region. Go here for details and to register.
  • 12-13 Sep 2022 (virtual, 9a-5p ET): This meeting of PACCARB is going to “identify key issues and critical policy gaps through a series of facilitated discussions examining a hypothetical large-scale disease outbreak scenario based on historic examples and estimates of future AMR outbreaks.” Sounds like pandemic wargaming (Center for Health Security; pre-COVID 19 May 2020 NPR article) to me! Go here for details.
  • 20-24 Sep 2022 (New Delhi): 21st Congress of the International Society for Human and Animal Mycology (ISHAM). Go here for details.
  • 4-7 Oct 2022 (Dublin, Ireland): The 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. This is an excellent meeting, especially for developers … and if you’ve missed it, the recordings from the 2021 meeting are online. Go here for details on the 2022 meeting.
  • 19-23 Oct 2022 (Washington, DC): IDWeek 2022, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Go here for details.
  • 15-23 Oct 2022 (in person, residential, Les Pensières, Veyrier-du-Lac, France): The 6th edition of Patrice Courvalin’s fabulous ICARe residential training course covering all things AMR is on for 2022! This is a soup-to-nuts training in AMR: it is very intense, very detailed, and always gets rave reviews from attendees. Registration is open 21 Mar 2022 to 21 June 2022 and is limited, so book your slot as soon as you can. Go here for details.
  • 19-23 Oct 2022 (Washington, DC): IDWeek 2022, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Go here for details.
  • 25-28 Oct 2022 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.
  • 17-20 Nov 2022 (Kuala Lumpur, Malaysia): The International Congress on Infectious Diseases will take place for the first time as a hybrid event. Go here for details. 
  • 27-30 Nov 2022 (Perth, Australia): 32nd International Congress of Antimicrobial Chemotherapy is the biennial congress of the International Society of Antimicrobial Chemotherapy (ISAC). Go here for details.

Share

HLM on AMR at UNGA: The end of the beginning

Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. Dear All (and with thanks to Damiano for co-authoring), Last week in NYC, the UN General Assembly (UNGA) and all its surrounding activities created a lot of energy (not to mention a giant traffic jam)! After a series of side meetings

Without action, AMR costs go from $66b to $159b/yr by 2050

Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout

UN TV: You can watch the AMR High-Level Meeting at UNGA

Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today.  You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD

PACE: A £5m funding round for diagnostics

Dear All, The peri-UNGA week is generating a lot of activity! Having about a year ago launched a £30m fund for support of AMR innovation with a call for therapeutic projects (30 Oct 2023 newsletter; I am told that awards will be announced soon), PACE (Pathways to Antimicrobial Clinical Efficacy, a joint project of LifeArc,

Scroll to Top